Process development of a serum-free and scalable lentiviral vector production in a single-use bioreactor
March 20 – 23, 2022
Lentiviral vectors (LV) have played a critical role in gene delivery for ex vivo gene-modified cell therapies, including T cells and NK cells; however, a large-scale manufacturing process is needed to cope with the increasing demand from the cell and gene therapy sector. Single-use fixed-bed bioreactors, such as the iCELLis bioreactor, provide a promising automated, scalable platform for the generation of large volumes of GMP-grade LV. Fixed-bed bioreactors have already been shown to generate high LV titers; nevertheless, most of the work currently undertaken in the field relies on serum-containing medium formulations. This is largely because to date serum-containing media produces higher viral titer yields and an increased LV stability during the down-stream processing of the product. However, relying on serum-based processes adds significant supply chain and manufacturing risk to the process.
Please click Additional Files below to see the full abstract.
Carme Ripoll Fiol, John Welsh, and Qasim Rafiq, "Process development of a serum-free and scalable lentiviral vector production in a single-use bioreactor" in "Single-Use Technologies V: Building The Future", Magali Barbaroux, Sartorius, France; Martina Micheletti, University College London, UK Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/sut_v/12